Collectively, these findings suggested that PCSK9 exerted immunomodulatory properties in atherosclerotic plaques and human blood through distinct molecular mechanisms, providing an immunological role for atherosclerosis attenuation beyond LDL-lowering. This evidence concerns the gene PCSK9 and atherosclerosis.